Akero and the associated logos are trademarks of Akero Therapeutics, Inc.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company developing transformative therapies for patients with serious metabolic diseases, with an initial focus on MASH (Metabolic dysfunction-associated steatohepatitis). Akero’s lead product candidate, efruxifermin (EFX), is a long-acting analog of fibroblast growth factor 21 (FGF21), a key hormone that regulates energy balance, lipid metabolism, insulin sensitivity, and inflammation—all critical drivers of MASH progression.

Efruxifermin is designed to be a first-in-class, once-weekly injectable therapy that acts on both the liver and systemic metabolic dysfunction, offering a comprehensive approach to treating MASH. It is currently being evaluated in multiple Phase 2b and Phase 3 clinical trials aimed at demonstrating improvement in liver histology, reduction of fibrosis, and resolution of steatohepatitis without worsening of liver disease. Clinical data to date have shown rapid and robust reductions in liver fat, improvements in fibrosis stage, and favorable metabolic effects—positioning EFX as a potentially disease-modifying therapy.

Akero’s therapeutic strategy centers on addressing both hepatic and cardiometabolic components of MASH through FGF21 analog signaling. By improving insulin sensitivity, reducing liver fat, and modulating inflammation and fibrosis, efruxifermin offers a promising pathway to halt or reverse disease progression in patients with limited treatment options.

Driven by a mission to change the trajectory of chronic liver disease, Akero is advancing a focused pipeline backed by rigorous science, a strong safety profile, and a commitment to patient-centered innovation. Through efruxifermin and future programs, Akero aims to set a new standard of care for MASH and related metabolic conditions.